Cardiac


Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
08 2021
Historique:
received: 24 07 2019
accepted: 22 08 2019
pubmed: 19 9 2019
medline: 9 2 2022
entrez: 19 9 2019
Statut: ppublish

Résumé

Cardiac Phantom calibration confirmed that cardiac uptake results from Japan could be applied to our center. We recruited 31 controls, 17 individuals with dementia with Lewy bodies (DLB) and 15 with Alzheimer's disease (AD). Images were acquired 20 minutes and four hours after injection using Siemens cameras with medium-energy low-penetration (MELP) collimators. Local normal heart-to-mediastinum (HMR) ratios were compared to Japanese results. Siemens gamma cameras with MELP collimators should give HMRs very close to the calibrated values used in Japan. However, our cut-offs with controls were lower at 2.07 for early and 1.86 for delayed images. Applying our lower cut-off to the dementia patients may increase the specificity of cardiac MIBG imaging for DLB diagnosis in a UK population without reducing sensitivity. Our local HMR cut-off values are lower than in Japan, higher than in a large US study but similar to those found in another UK center. UK centers using other cameras and collimators may need to use different cut-offs to apply our results.

Identifiants

pubmed: 31529384
doi: 10.1007/s12350-019-01887-6
pii: 10.1007/s12350-019-01887-6
doi:

Substances chimiques

Iodine Radioisotopes 0
Radiopharmaceuticals 0
3-Iodobenzylguanidine 35MRW7B4AD
Iodine-123 8YWR746RPQ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1692-1701

Subventions

Organisme : Medical Research Council
ID : G1100540
Pays : United Kingdom

Informations de copyright

© 2019. American Society of Nuclear Cardiology.

Références

Vann SA, Orien JT. The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies. Psychol Med 2014;44:673-83.
doi: 10.1017/S0033291713000494
Kane JPM, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther 2018;10:19.
pubmed: 29448953 pmcid: 5815202 doi: 10.1186/s13195-018-0350-6
Hanyu H, et al. Differences in clinical course between dementia with Lewy bodies and Alzheimer’s disease. Eur J Neurol 2009;16:212-7.
pubmed: 19146642 doi: 10.1111/j.1468-1331.2008.02388.x
Lee DR, et al. Examining carer stress in dementia: The role of subtype diagnosis and neuropsychiatric symptoms. Int J Geriatr Psychiatry 2013;28:135-41.
pubmed: 22422615 doi: 10.1002/gps.3799
Galvin JE, et al. Lewy body dementia: The caregiver experience of clinical care. Parkinsonism Relat Disord 2010;16:388-92.
pubmed: 20434939 pmcid: 2916037 doi: 10.1016/j.parkreldis.2010.03.007
McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89:88-100.
pubmed: 28592453 pmcid: 5496518 doi: 10.1212/WNL.0000000000004058
Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther 2014;6:46.
pubmed: 25484925 pmcid: 4255387 doi: 10.1186/alzrt274
Schneider JA, et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012;135:3005-14.
pubmed: 23065790 pmcid: 3470712 doi: 10.1093/brain/aws234
Roberts G, et al. A comparison of visual and semiquantitative analysis methods for planar cardiac 123I-MIBG scintigraphy in dementia with Lewy bodies. Nucl Med Commun 2019;40:734-43.
pubmed: 31058746 doi: 10.1097/MNM.0000000000001024
Kane JPM, et al. (123)I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort. Parkinsonism Relat Disord 2019;62:79-84.
pubmed: 30709778 doi: 10.1016/j.parkreldis.2019.01.024
Nakajima K, et al. Standardization of
pubmed: 28596948 pmcid: 5437131 doi: 10.1007/s40336-017-0230-2
Verberne HJ, et al. Vascular time-activity variation in patients undergoing
doi: 10.1007/s00259-011-1783-3
Verschure DO, et al.
doi: 10.1097/MNM.0000000000000238
Verschure DO, et al. A European myocardial 123I-mIBG cross-calibration phantom study. J Nucl Cardiol 2017;25:1191-7.
pubmed: 28120154 pmcid: 6133137 doi: 10.1007/s12350-017-0782-6
Slomka P, et al. Quantification of I-123-meta-iodobenzylguanidine Heart-to-Mediastinum Ratios: Not So Simple After All. J Nucl Cardiol 2014;21:979-83.
pubmed: 25005347 doi: 10.1007/s12350-014-9943-z
Klene C, et al. Influence of ROI definition on the heart-to-mediastinum ratio in planar 123I-MIBG imaging. J Nucl Cardiol 2016;25:208-16.
pubmed: 27804071 doi: 10.1007/s12350-016-0708-8
Flotats A, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37:1802-12.
pubmed: 20577740 doi: 10.1007/s00259-010-1491-4
Jacobson AF, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
pubmed: 20188504 doi: 10.1016/j.jacc.2010.01.014
Nakajima K, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol 2014;21:970-8.
pubmed: 24942608 pmcid: 4167440 doi: 10.1007/s12350-014-9916-2
Nakajima K, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: Effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging 2012;39:113-9.
pubmed: 22009380 doi: 10.1007/s00259-011-1963-1
Yoshita M, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: A multicenter study. PLoS ONE 2015;10:e0120540.
pubmed: 25793585 pmcid: 4368705 doi: 10.1371/journal.pone.0120540
Komatsu J, et al. (123)I-MIBG myocardial scintigraphy for the diagnosis of DLB: A multicentre 3-year follow-up study. J Neurol Neurosurg Psychiatry 2018;89:1167-73.
pubmed: 29853532 doi: 10.1136/jnnp-2017-317398
Waqar F, Gerson MC. Cardiac sympathetic imaging in the diagnosis of cardiac autonomic neuropathy in pre-diabetes. J Nucl Cardiol 2015;22:1269-72.
pubmed: 25736176 doi: 10.1007/s12350-015-0082-y
Asghar O, et al. Individuals with impaired glucose tolerance demonstrate normal cardiac sympathetic innervation using I-123 mIBG scintigraphy. J Nucl Cardiol 2015;22:1262-8.
pubmed: 25698476 doi: 10.1007/s12350-015-0070-2
Beach TG, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
pubmed: 20306269 pmcid: 2866090 doi: 10.1007/s00401-010-0664-3
Nakajima K, et al. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med 2016;30:188-99.
pubmed: 26897008 pmcid: 4819542 doi: 10.1007/s12149-016-1065-z
Asghar O, et al. Iodine-123 metaiodobenzylguanidine scintigraphy for the assessment of cardiac sympathetic innervation and the relationship with cardiac autonomic function in healthy adults using standardized methods. Nucl Med Commun 2017;38:44-50.
pubmed: 27898646 pmcid: 5131722 doi: 10.1097/MNM.0000000000000608
Yoshita M, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006;66:1850-4.
pubmed: 16801649 doi: 10.1212/01.wnl.0000219640.59984.a7
Sakamoto F, et al. 123I-MIBG myocardial scintigraphy for the evaluation of Lewy body disease: Are delayed images essential? Is visual assessment useful? Br J Radiol 2016;89:20160144.
pubmed: 27222274 pmcid: 5124887 doi: 10.1259/bjr.20160144
Chung EJ, Kim SJ. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Lewy body-related disorders: A literature review. J Mov Disord 2015;8:55-66.
pubmed: 26090077 pmcid: 4460541 doi: 10.14802/jmd.15015
Orimo S, et al. (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in alpha-synucleinopathies. Ageing Res Rev 2016;30:122-33.
pubmed: 26835846 doi: 10.1016/j.arr.2016.01.001
Sonni I, et al. Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiol Aging 2017;52:228-42.
pubmed: 28317651 doi: 10.1016/j.neurobiolaging.2016.04.026
Verberne HJ, et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29:1147-59.
pubmed: 18349024 doi: 10.1093/eurheartj/ehn113
Travin MI, et al. How do we establish cardiac sympathetic nervous system imaging with (123)I-mIBG in clinical practice? Perspectives and lessons from Japan and the US. J Nucl Cardiol 2018;26:1434-51.
pubmed: 30178272 doi: 10.1007/s12350-018-1394-5
Jacobson AF, et al. Impact of age on myocardial uptake of (1)(2)(3)I-mIBG in older adult subjects without coronary heart disease. J Nucl Cardiol 2013;20:406-14.
pubmed: 23483457 doi: 10.1007/s12350-013-9701-7
Nakajima K, et al. The time has come to standardize (123)I-MIBG heart-to-mediastinum ratios including planar and SPECT methods. Eur J Nucl Med Mol Imaging 2016;43:386-8.
pubmed: 26592939 doi: 10.1007/s00259-015-3258-4
Jacobson AF, et al. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.
pubmed: 19152136 doi: 10.1007/s12350-008-9008-2
Jacobson AF, et al. Impact of age on myocardial uptake of 123I-mIBG in older adult subjects without coronary heart disease. J Nucl Cardiol 2013;20:9.
doi: 10.1007/s12350-013-9701-7
Nakajima K, et al. Is (123)I-metaiodobenzylguanidine heart-to-mediastinum ratio dependent on age? From Japanese Society of Nuclear Medicine normal database. Ann Nucl Med 2018;32:175-81.
pubmed: 29333564 pmcid: 5852176 doi: 10.1007/s12149-018-1231-6
Nakata T, et al. Regional cardiac sympathetic nerve dysfunction and the diagnostic efficacy of metaiodobenzylguanidine tomography in stable coronary artery disease. Am J Cardiol 1996;78:292-7.
pubmed: 8759807 doi: 10.1016/S0002-9149(96)00280-9
Travin MI. Potential for adrenergic imaging to serve as a unique tool for guidance of patient management during and after an acute ischemic event. J Nucl Cardiol 2018;25:581-5.
pubmed: 27650444 doi: 10.1007/s12350-016-0675-0
Fallavollita JA, Canty JM Jr. Dysinnervated but viable myocardium in ischemic heart disease. J Nucl Cardiol 2010;17:1107-15.
pubmed: 20857351 pmcid: 3026632 doi: 10.1007/s12350-010-9292-5
Hinton W, et al. Incidence and prevalence of cardiovascular disease in English primary care: A cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). BMJ Open 2018;8:e020282.
pubmed: 30127048 pmcid: 6104756 doi: 10.1136/bmjopen-2017-020282
Digital, N., Quality and outcomes framework, achievement, prevalence and exceptions data: 2017-2018. Quality and Outcomes Framework (QOF), 2018.
Kitamura A, et al. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: The Akita-Osaka study. J Am Coll Cardiol 2008;52:71-9.
pubmed: 18582638 doi: 10.1016/j.jacc.2008.02.075
Pellegrino T, et al. Impact of obesity and acquisition protocol on (123)I-metaiodobenzylguanidine indexes of cardiac sympathetic innervation. Quant Imaging Med Surg 2015;5:822-8.
pubmed: 26807364 pmcid: 4700238
Bradbury KE, et al. Association between physical activity and body fat percentage, with adjustment for BMI: A large cross-sectional analysis of UK Biobank. BMJ Open 2017;7:e011843.
pubmed: 28341684 pmcid: 5372047 doi: 10.1136/bmjopen-2016-011843
Cui R, et al. Body mass index and mortality from cardiovascular disease among Japanese men and women: The JACC study. Stroke 2005;36:1377-82.
pubmed: 15920029 doi: 10.1161/01.STR.0000169925.57251.4e

Auteurs

G Roberts (G)

Institute of Neuroscience, Newcastle University, Biomedical Research Building, Campus for Ageing and Vitality, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK. gemma.roberts@newcastle.ac.uk.
Nuclear Medicine Department, Leazes Wing, Royal Victoria Infirmary, Richardson Road, Newcastle upon Tyne, NE1 4LP, UK. gemma.roberts@newcastle.ac.uk.

J J Lloyd (JJ)

Institute of Neuroscience, Newcastle University, Biomedical Research Building, Campus for Ageing and Vitality, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK.
Nuclear Medicine Department, Leazes Wing, Royal Victoria Infirmary, Richardson Road, Newcastle upon Tyne, NE1 4LP, UK.

J P M Kane (JPM)

Institute of Neuroscience, Newcastle University, Biomedical Research Building, Campus for Ageing and Vitality, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK.

R Durcan (R)

Institute of Neuroscience, Newcastle University, Biomedical Research Building, Campus for Ageing and Vitality, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK.

S Lawley (S)

Institute of Neuroscience, Newcastle University, Biomedical Research Building, Campus for Ageing and Vitality, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK.

K Howe (K)

Nuclear Medicine Department, Leazes Wing, Royal Victoria Infirmary, Richardson Road, Newcastle upon Tyne, NE1 4LP, UK.

G S Petrides (GS)

Nuclear Medicine Department, Leazes Wing, Royal Victoria Infirmary, Richardson Road, Newcastle upon Tyne, NE1 4LP, UK.

J T O'Brien (JT)

Department of Psychiatry, University of Cambridge, Box 189, Level E4 Cambridge Biomedical Campus, Cambridge, CB2 0SP, UK.

A J Thomas (AJ)

Institute of Neuroscience, Newcastle University, Biomedical Research Building, Campus for Ageing and Vitality, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH